Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Dr. Arie S. Belldegrun, MD, FACS Joins Two River Group Holdings as Chairman and Partner
May 18th, 2008
Two River Group Holdings, LLC, a biotechnology focused venture capital company, is pleased to announce that Dr. Arie Belldegrun, MD, FACS has joined as Chairman and Partner. Dr. Belldegrun is Professor and Chief of Urologic Oncology, and holds the Carol and Roy Doumani Chair in Urologic Oncology, at the David Geffen School of Medicine at the University of California, Los Angeles. He received his medical degree at the Hebrew University Hadassah Medical School, and conducted his post-doctoral studies at the Weizmann Institute of Science in Israel. He completed his Urologic Surgery residency at Harvard Medical School in 1985 and his Surgical Oncology fellowship at the...
Source: Medical Letter on the CDC & FDA (2008-05-18)
|
